Skip to main contentSkip to navigation
Peptide Atlas
Back to Case Studies
Protocol ExampleCJC-12958 weeksPositive Outcome

CJC-1295 and Ipamorelin Stack: Recovery Protocol

A protocol example for using CJC-1295 in combination with Ipamorelin for recovery and performance support.

March 10, 2024Anonymized

Research Use Only

This case study is for educational and research purposes only. It should not be considered medical advice. Always consult with qualified healthcare providers before considering any peptide protocols. Individual results may vary.

This case study outlines a research protocol for using CJC-1295 in combination with Ipamorelin. The protocol was designed for recovery and performance support in a research setting. **Background:** The research participant was interested in exploring the research applications of growth hormone-releasing peptides. The protocol combined CJC-1295 with Ipamorelin in a specific dosing schedule. **Protocol Structure:** The protocol followed a structured approach with specific dosing times and injection protocols. Both peptides were administered according to research guidelines. **Key Observations:** - Protocol was well-structured - Dosing schedule was maintained - Regular monitoring was conducted - Research parameters were followed **Important Notes:** This is a research protocol example only. Peptide stacking should only be done under medical supervision and in appropriate research settings. This case study is for educational purposes.

Protocol

1Week 1

Dosage: CJC-1295: 1 mg, Ipamorelin: 200 mcg

Frequency: Once daily (before bed)

Notes: Initial protocol start

2Week 2

Dosage: CJC-1295: 1 mg, Ipamorelin: 200 mcg

Frequency: Once daily (before bed)

Notes: Continued protocol

3Week 3

Dosage: CJC-1295: 1 mg, Ipamorelin: 200 mcg

Frequency: Once daily (before bed)

Notes: Continued protocol

4Week 4

Dosage: CJC-1295: 1 mg, Ipamorelin: 200 mcg

Frequency: Once daily (before bed)

Notes: Mid-protocol assessment

5Week 5

Dosage: CJC-1295: 1 mg, Ipamorelin: 200 mcg

Frequency: Once daily (before bed)

Notes: Continued protocol

6Week 6

Dosage: CJC-1295: 1 mg, Ipamorelin: 200 mcg

Frequency: Once daily (before bed)

Notes: Continued protocol

7Week 7

Dosage: CJC-1295: 1 mg, Ipamorelin: 200 mcg

Frequency: Once daily (before bed)

Notes: Continued protocol

8Week 8

Dosage: CJC-1295: 1 mg, Ipamorelin: 200 mcg

Frequency: Once daily (before bed)

Notes: Final week of protocol

Outcome

The research protocol was completed successfully. The stacking protocol was well-tolerated, and research parameters were maintained throughout. This is a research example only.

Key Findings

  • Stacking protocol was well-structured
  • Dosing schedule was maintained
  • Research parameters were followed
  • Protocol completion was successful

Lessons Learned

  • Stacking requires careful planning
  • Dosing timing is important
  • Regular monitoring is essential
  • Research protocols must be followed precisely
stackingrecoveryperformanceprotocol